MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Ironwood Pharmaceuticals Inc

Open

BrancheGesundheitswesen

0.88 10

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

0.8

Max

0.89

Schlüsselkennzahlen

By Trading Economics

Einkommen

-1.4M

2.3M

Verkäufe

-1M

91M

KGV

Branchendurchschnitt

70.49

57.333

EPS

0.02

Gewinnspanne

2.492

Angestellte

253

EBITDA

6.1M

33M

Dividenden

By Dow Jones

Nächstes Ergebnis

8. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-249M

118M

Vorheriger Eröffnungskurs

-9.12

Vorheriger Schlusskurs

0.88

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

Ironwood Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

14. Apr. 2025, 14:26 UTC

Wichtige Markttreiber

Ironwood Pharma Shares Fall on Word of Confirmatory Phase 3 Apraglutide Trial

Peer-Vergleich

Kursveränderung

Ironwood Pharmaceuticals Inc Prognose

Rating-Konsens

By TipRanks

Neutral

6 ratings

0

Buy

6

Halten

0

Sell

Technischer Score

By Trading Central

0.7222 / 0.9055Unterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Weak Bearish Evidence

Langfristig

Weak Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.